{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:29:06Z","timestamp":1790368146573,"version":"4.1.0"},"reference-count":55,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2016.0261","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:27:14Z","timestamp":1525238834000},"source":"Crossref","is-referenced-by-count":33,"title":["The Treatment of Disorders of Lipid Metabolism"],"prefix":"10.3238","author":[{"given":"Klaus G.","family":"Parhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"10.3238\/arztebl.2016.0261_ref1","unstructured":"Anitschkow N, Chalatow S: \u00dcber experimentelle Cholesterinsteatose und ihre Bedeutung f\u00fcr die Entstehung einiger pathologischer Prozesse. Centralbl Allg Pathol Pathol Anatomie 1913; 14: 1\u20139."},{"key":"10.3238\/arztebl.2016.0261_ref2","doi-asserted-by":"crossref","unstructured":"Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol 2010; 105: 1802\u20138","DOI":"10.1016\/j.amjcard.2010.01.363"},{"key":"10.3238\/arztebl.2016.0261_ref3","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383\u20139","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"10.3238\/arztebl.2016.0261_ref4","doi-asserted-by":"crossref","unstructured":"Baigent C, Blackwell L, Emberson J, et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670\u201381","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"10.3238\/arztebl.2016.0261_ref5","doi-asserted-by":"crossref","unstructured":"Taylor F, Huffman MD, Macedo AF, et al.: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"10.3238\/arztebl.2016.0261_ref6","doi-asserted-by":"crossref","unstructured":"Watts GF, Gidding S, Wierzbicki AS, et al.: Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171: 309\u201325","DOI":"10.1016\/j.ijcard.2013.11.025"},{"key":"10.3238\/arztebl.2016.0261_ref7","doi-asserted-by":"crossref","unstructured":"Ference BA, Yoo W, Alesh I, et al.: Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631\u20139","DOI":"10.1016\/j.jacc.2012.09.017"},{"key":"10.3238\/arztebl.2016.0261_ref8","doi-asserted-by":"crossref","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.: Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387\u201397","DOI":"10.1056\/NEJMoa1410489"},{"key":"10.3238\/arztebl.2016.0261_ref9","doi-asserted-by":"crossref","unstructured":"Boekholdt SM, Hovingh GK, Mora S, et al.: Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64: 485\u201394","DOI":"10.1016\/j.jacc.2014.02.615"},{"key":"10.3238\/arztebl.2016.0261_ref10","doi-asserted-by":"crossref","unstructured":"Robinson JG, Farnier M, Krempf M, et al.: Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489\u201399","DOI":"10.1056\/NEJMoa1501031"},{"key":"10.3238\/arztebl.2016.0261_ref11","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al.: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500\u20139","DOI":"10.1056\/NEJMoa1500858"},{"key":"10.3238\/arztebl.2016.0261_ref12","doi-asserted-by":"crossref","unstructured":"Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A: Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371: 32\u201341","DOI":"10.1056\/NEJMoa1308027"},{"key":"10.3238\/arztebl.2016.0261_ref13","doi-asserted-by":"crossref","unstructured":"Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A: Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34: 1826\u201333","DOI":"10.1093\/eurheartj\/ehs431"},{"key":"10.3238\/arztebl.2016.0261_ref14","doi-asserted-by":"crossref","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG: Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427\u201336","DOI":"10.1016\/j.jacc.2012.08.1026"},{"key":"10.3238\/arztebl.2016.0261_ref15","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Olsson AG, Abt M, et al.: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089\u201399","DOI":"10.1056\/NEJMoa1206797"},{"key":"10.3238\/arztebl.2016.0261_ref16","doi-asserted-by":"crossref","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al.: Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844\u201353","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"10.3238\/arztebl.2016.0261_ref17","doi-asserted-by":"crossref","unstructured":"Parhofer KG: Lipoprotein(a): Medical treatment options for an elusive molecule. Curr Pharm Design 2011; 17: 871\u20136","DOI":"10.2174\/138161211795428777"},{"key":"10.3238\/arztebl.2016.0261_ref18","doi-asserted-by":"crossref","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, et al.: 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: 49\u201373","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"10.3238\/arztebl.2016.0261_ref19","doi-asserted-by":"crossref","unstructured":"Catapano AL, Reiner Z, De Backer G, et al.: ESC\/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3\u201346","DOI":"10.1016\/j.atherosclerosis.2011.06.028"},{"key":"10.3238\/arztebl.2016.0261_ref20","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Tuzcu EM, Sipahi I, et al.: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499\u2013508","DOI":"10.1001\/jama.297.5.499"},{"key":"10.3238\/arztebl.2016.0261_ref21","doi-asserted-by":"crossref","unstructured":"Wei L, MacDonald TM, Watson AD, Murphy MJ: Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007; 16: 385\u201392","DOI":"10.1002\/pds.1297"},{"key":"10.3238\/arztebl.2016.0261_ref22","doi-asserted-by":"crossref","unstructured":"Mihaylova B, Emberson J, Blackwell L, et al.: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581\u201390","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"10.3238\/arztebl.2016.0261_ref23","doi-asserted-by":"crossref","unstructured":"Ridker PM, MacFadyen JG, Fonseca FA, et al.: Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009; 2: 616\u201323","DOI":"10.1161\/CIRCOUTCOMES.109.848473"},{"key":"10.3238\/arztebl.2016.0261_ref24","doi-asserted-by":"crossref","unstructured":"Malhotra A, Shafiq N, Arora A, Singh M, Kumar R, Malhotra S: Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev 2014; 6: CD001918","DOI":"10.1002\/14651858.CD001918.pub3"},{"key":"10.3238\/arztebl.2016.0261_ref25","doi-asserted-by":"crossref","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, et al.: The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2: 655\u201366","DOI":"10.1016\/S2213-8587(13)70191-8"},{"key":"10.3238\/arztebl.2016.0261_ref26","doi-asserted-by":"crossref","unstructured":"Estruch R, Ros E, Salas-Salvado J, et al.: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279\u201390","DOI":"10.1056\/NEJMoa1200303"},{"key":"10.3238\/arztebl.2016.0261_ref27","doi-asserted-by":"crossref","unstructured":"Bao Y, Han J, Hu FB, et al.: Association of nut consumption with total and cause-specific mortality. N Engl J Med 2013; 369: 2001\u201311","DOI":"10.1056\/NEJMoa1307352"},{"key":"10.3238\/arztebl.2016.0261_ref28","doi-asserted-by":"crossref","unstructured":"Wu L, Piotrowski K, Rau T, et al.: Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. Metabolism 2014; 63: 382\u201391","DOI":"10.1016\/j.metabol.2013.11.005"},{"key":"10.3238\/arztebl.2016.0261_ref29","doi-asserted-by":"crossref","unstructured":"Roffi M, Patrono C, Collet JP, et al.: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016 14; 37: 267\u2013315","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"10.3238\/arztebl.2016.0261_ref30","doi-asserted-by":"crossref","unstructured":"Stroes ES, Thompson PD, Corsini A, et al.: Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012\u201322","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"10.3238\/arztebl.2016.0261_ref31","doi-asserted-by":"crossref","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495\u2013504","DOI":"10.1056\/NEJMoa040583"},{"key":"10.3238\/arztebl.2016.0261_ref32","doi-asserted-by":"crossref","unstructured":"Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674\u20138","DOI":"10.1161\/01.CIR.0000137828.06205.87"},{"key":"10.3238\/arztebl.2016.0261_ref33","doi-asserted-by":"crossref","unstructured":"Sparrow CP, Burton CA, Hernandez M, et al.: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115\u201321","DOI":"10.1161\/01.ATV.21.1.115"},{"key":"10.3238\/arztebl.2016.0261_ref34","doi-asserted-by":"crossref","unstructured":"Vale N, Nordmann AJ, Schwartz GG, et al.: Statins for acute coronary syndrome. Cochrane Database Syst Rev 2014; 9: CD006870","DOI":"10.1002\/14651858.CD006870.pub3"},{"key":"10.3238\/arztebl.2016.0261_ref35","doi-asserted-by":"crossref","unstructured":"Wu L, Parhofer KG: Diabetic dyslipidemia. Metabolism 2014; 63: 1469\u201379","DOI":"10.1016\/j.metabol.2014.08.010"},{"key":"10.3238\/arztebl.2016.0261_ref36","doi-asserted-by":"crossref","unstructured":"Bosch J, Gerstein HC, Dagenais GR, et al.: n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367: 309\u201318","DOI":"10.1056\/NEJMoa1203859"},{"key":"10.3238\/arztebl.2016.0261_ref37","doi-asserted-by":"crossref","unstructured":"Ginsberg HN, Elam MB, Lovato LC, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563\u201374","DOI":"10.1056\/NEJMoa1001282"},{"key":"10.3238\/arztebl.2016.0261_ref38","doi-asserted-by":"crossref","unstructured":"Kromhout D, Giltay EJ, Geleijnse JM: n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363: 2015\u201326","DOI":"10.1056\/NEJMoa1003603"},{"key":"10.3238\/arztebl.2016.0261_ref39","doi-asserted-by":"crossref","unstructured":"Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto miocardico: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447\u201355","DOI":"10.1016\/S0140-6736(99)07072-5"},{"key":"10.3238\/arztebl.2016.0261_ref40","doi-asserted-by":"crossref","unstructured":"Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410\u20138","DOI":"10.1056\/NEJM199908053410604"},{"key":"10.3238\/arztebl.2016.0261_ref41","doi-asserted-by":"crossref","unstructured":"Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237\u201345","DOI":"10.1056\/NEJM198711123172001"},{"key":"10.3238\/arztebl.2016.0261_ref42","doi-asserted-by":"crossref","unstructured":"Tsimikas S, Viney NJ, Hughes SG, et al.: Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015","DOI":"10.1016\/S0140-6736(15)61252-1"},{"key":"10.3238\/arztebl.2016.0261_ref43","doi-asserted-by":"crossref","unstructured":"Briel M, Ferreira-Gonzalez I, You JJ, et al.: Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338: b92.","DOI":"10.1136\/bmj.b92"},{"key":"10.3238\/arztebl.2016.0261_ref44","doi-asserted-by":"crossref","unstructured":"Stein EA, Gipe D, Bergeron J, et al.: Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet\u00a02012; 380: 29\u201336","DOI":"10.1016\/S0140-6736(12)60771-5"},{"key":"10.3238\/arztebl.2016.0261_ref45","doi-asserted-by":"crossref","unstructured":"Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ: Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128: 2113\u201320","DOI":"10.1161\/CIRCULATIONAHA.113.004678"},{"key":"10.3238\/arztebl.2016.0261_ref46","doi-asserted-by":"crossref","unstructured":"Blom DJ, Hala T, Bolognese M, et al.: A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809\u201319","DOI":"10.1056\/NEJMoa1316222"},{"key":"10.3238\/arztebl.2016.0261_ref47","doi-asserted-by":"crossref","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, et al.: Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63: 1278\u201388","DOI":"10.1016\/j.jacc.2014.01.006"},{"key":"10.3238\/arztebl.2016.0261_ref48","doi-asserted-by":"crossref","unstructured":"Baigent C, Landray MJ, Reith C, et al.: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181\u201392","DOI":"10.1016\/j.ymed.2011.08.055"},{"key":"10.3238\/arztebl.2016.0261_ref49","doi-asserted-by":"crossref","unstructured":"Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351\u201364.","DOI":"10.1001\/jama.251.3.351"},{"key":"10.3238\/arztebl.2016.0261_ref50","doi-asserted-by":"crossref","unstructured":"Bruckert E, Labreuche J, Amarenco P: Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210: 353\u201361","DOI":"10.1016\/j.atherosclerosis.2009.12.023"},{"key":"10.3238\/arztebl.2016.0261_ref51","doi-asserted-by":"crossref","unstructured":"Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245\u201355","DOI":"10.1016\/S0735-1097(86)80293-5"},{"key":"10.3238\/arztebl.2016.0261_ref52","doi-asserted-by":"crossref","unstructured":"Boden WE, Probstfield JL, Anderson T, et al.: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255\u201367","DOI":"10.1056\/NEJMoa1107579"},{"key":"10.3238\/arztebl.2016.0261_ref53","doi-asserted-by":"crossref","unstructured":"Landray MJ, Haynes R, Hopewell JC, et al.: Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203\u201312","DOI":"10.1056\/NEJMoa1300955"},{"key":"10.3238\/arztebl.2016.0261_ref54","doi-asserted-by":"crossref","unstructured":"Jun M, Foote C, Lv J, et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875\u201384","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"10.3238\/arztebl.2016.0261_ref55","doi-asserted-by":"crossref","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, et al.: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478\u201390","DOI":"10.1093\/eurheartj\/eht273"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:25:57Z","timestamp":1638779157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":55,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2016.0261","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1007\/s11428-017-0233-7","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]}}}